Fig. 1.

PKC412, a specific FLT3ITD inhibitor, downregulates hTERT expression and telomerase activity in FLT3ITD-carrying AML cells. a, b The time- and dose-dependent inhibitions of FLT3 phosphorylation in PKC412-treated MV4,11 (a) and MOLM-13 cells (b). Immunoblotting was performed. and one of three independent experiments is shown. c, d PKC412-induced downregulation of hTERT expression and telomerase activity in MV4,11 (c) and MOLM-13 cells (d) in time- and dose-dependent manners. hTERT mRNA expression was determined using qPCR, and the level of hTERT mRNA was arbitrarily calculated based on CT values normalized with β2-M expression. e, f The downregulated telomerase activity in MV4,11 (e) and MOLM-13 cells (f) treated with PKC-412. The level of telomerase activity was assessed using a telomerase ELISA kit and expressed as absorbance in arbitrary units. g The downregulation of hTERT mRNA in primary FLT3ITD-carrying leukemic cells treated with PKC-412. Leukemic cells were derived from two patients with AML and incubated in the presence of different concentrations of PKC412 for 24 h. hTERT mRNA expression level was determined using qPCR. *P < 0.05; ** P < 0.01. Student’s t test was performed. All the results shown were from three independent experiments